Introduction
Osteoporosis and fractures are major complications of glucocorticoid (GC) therapy. From epidemiological studies, a significant number of the population are at risk; about 2% of the elderly population use oral GCs in the United Kingdom [1] and in the United States, between 1999 and 2008, 1.2% of the population (in the National Health and Nutrition Examination Survey (NHANES) database) were on GC, with 28.8% taking GC for more than 5 years [2] . Many of the inflammatory conditions that may require GC usage are already associated with an increased risk of fracture [3] . The addition of GC Fig. 1 . Approach to postmenopausal women and men age >50 years initiating or receiving glucocorticoid therapy [17] . therapy increases risk of sustaining fractures over and above that of the underlying disorder [4] (Level III).
Bone loss occurs most rapidly in the first 6e12 months of oral GC therapy [5] , with an increase in fracture risk that appears within 3e6 months of starting GC [5, 6] (Level Ia) . Thus, it is important to consider bone protective strategies at the onset of GC therapy. Furthermore, at similar levels of bone mineral density (BMD), postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture [7] (Level Ib).
Prednisolone ! 5 mg daily or its equivalent, for more than 3 months is associated with osteoporosis and an increased risk of fractures [8] , but doses of prednisolone 2.5 mg daily have also been associated with an increased relative risk of vertebral fracture [6] (Level III).
Standard doses of inhaled or topical GC use have not been shown to adversely affect BMD. However, the cumulative inhaled GC dose in asthmatics have been inversely associated with BMD [9] and inhaled high potency GC usage (greater than 1500 mg daily) have been associated with both vertebral [10] and hip fractures [11] (Level IIa).
Methods
The previous Clinical Practice Guidelines published in 2012 was used as the baseline. To update the document, a systematic review and literature search by the members of the Working Group, using PubMed (MEDLINE), identified all relevant articles on GIO and its assessment, diagnosis and treatment, from 1st January 2011 to 31st December 2015. The date 2011 rather than 2012 was chosen so that all studies published just before and after the last guidelines would be reviewed and none inadvertently overlooked. The search on PubMed using the keywords "glucocorticoid" and "osteoporosis" during the above time frame, limited by "Human" and "English", produced 527 articles. Of these, 158 were on osteoporosis in general unrelated to GIO, 131 were studies that did not have any relationship to GIO for example, studies using GC in various diseases, 38 were on childhood GIO/GC usage, and 69 were studies related to the molecular mechanism of action of GC; this left 131 studies that were further assessed for this paper. A search of the Cochrane Library website (www.cochrane.org) from 1st January 2011 to 10th October 2016, just before this manuscript was completed showed 1 new review "Bisphosphonates for treating osteoporosis caused by the use of steroids" published in 5 October 2016.
The studies were assessed by 2 of the Working Group members and those that were used in the Clinical Guidance were graded with the levels of evidence as used by the National Guideline Clearinghouse, Agency for Healthcare Research and Quality, U.S. Department of Health & Human Services, USA [12] (Appendix 1). For each statement, studies with the highest levels of evidence were used to frame the statements. The grade of recommendation was taken from the Scottish Intercollegiate Guidelines Network grading system [13] (Appendix 1).
Results and discussion

Assessing risk and diagnosis
The use of BMD measurement for the diagnosis of GIO is not crucial, but may be useful in the monitoring of therapy. BMD should be measured at the lumbar spine and hip by dualenergy X-ray absorptiometry (DXA), although the lumbar spine measurement may be artefactually elevated in the elderly due to degenerative changes [14] . As there are data showing that postmenopausal women taking GC have a higher fracture risk compared to those not taking GC at a similar BMD [7] , a treatment threshold at a T-score of <À1.5 has been suggested [14, 15] . Diagnostic thresholds in GIO have not been established for peripheral densitometry using either DXA or ultrasound, which therefore should not be used for assessment or monitoring [14] .
The more recent GIO guidelines have used Fracture Risk Assessment Tool (FRAX) [16] to categorise patients into low, medium and high risk groups with respect to the 10-year risk of fracture, rather than relying on BMD measurement alone.
In postmenopausal women and men over 50 years old with low risk of fracture, treatment is recommended when prednisolone (or its equivalent) ! 7.5 mg daily is taken for more than 3 months. In medium risk patients, treatment is recommended at any dose of GC when taken for more than 3 months. In high risk patients, treatment is suggested for any dose of GC taken for any length of time [17] (see Fig. 1 ). In addition to the calculated FRAX risk estimates, Table 1 lists the clinical factors that may shift an individual to a greater risk category for GIO [17] .
For premenopausal women of non-childbearing potential and men under 50 years old with a prevalent osteoporotic fracture, treatment is recommended if prednisolone ! 5 mg daily is given for >1 month. For premenopausal women of childbearing potential, treatment is recommended when prednisolone ! 7.5 mg daily is given for >3 months [17] (see Fig. 2 ).
There has been a recommendation that the FRAX risk estimates should be adjusted according to the daily dose of GC. For low-dose exposure (< 2.5 mg daily of prednisolone or equivalent), the probability of a major fracture is decreased by about 20% depending on age. For medium doses (2.5e7.5 mg daily), the unadjusted FRAX value can be used. For high doses Table 1 Clinical factors that may shift an individual to a greater risk category for glucocorticoid-induced osteoporosis [17] .
Low body mass index Parental history of hip fracture Current smoking ! 3 alcoholic drinks per day Higher daily glucocorticoid dose Higher cumulative glucocorticoid usage Intravenous pulse glucocorticoid usage Declining central bone mineral density measurement that exceeds the least significant change Fig. 2 . Approach to premenopausal women and men age <50 years initiating or receiving glucocorticoid therapy [17] .
(> 7.5 mg daily), probabilities can be revised upward by about 15% [18] .
Treatment options
General measures
a) Prescribing the lowest effective dose of GC for the shortest period of time for good disease control [17] . b) The use of alternative route of administration [14] (e.g. inhaled GC in asthma) c) Consider the use of GC-sparing agents d) Modification of lifestyle -adequate calcium intake, adequate mobilisation, regular weight-bearing exercise, stopping smoking, avoiding excessive alcohol intake (<2 drinks per day) and prevention of falls [17] (Grade C, Level IV)
Specific measures
In hypogonadal states, replacement therapy with sex steroids should be considered (Grade A, Level Ib).
All patients on GC should be supplemented with calcium and vitamin D (1000e1500 mg/day and 800 IU/day respectively) [19, 20] (Grade A, Level Ia).
Drugs that have been shown to be effective in GIO are shown in Table 2 . The management algorithm for the management of postmenopausal women and men over the age of 50 years on GC is shown in Fig. 1 and for premenopausal women and men under the age of 50 is shown in Fig. 2 .
In patients on GC with osteoporotic fractures or confirmed osteoporosis on DXA, bisphosphonates are the first-line treatment (Grade A, Level Ib).
In a study comparing alendronate, vitamin D and calcitriol, alendronate increased lumbar spine BMD by 5.9% over 2 years, compared to 0.5% and 0.7% loss on vitamin D and calcitriol respectively. There was no difference at the femoral neck [21] . In a prevention study comparing alendronate and alfacalcidol over 18 months, patients on alendronate maintained or improved their lumbar spine and femoral neck BMD compared to BMD loss in the alfacalcidol group [22] . IV zoledronate produced a better gain in lumbar spine and femoral neck BMD compared to oral risedronate over 1 year [23] . Over 3 years, teriparatide led to a better gain in lumbar spine and femoral neck BMD and reduced the incidence of new vertebral fractures compared to alendronate [24] . Alendronate and risedronate also reduced vertebral fractures in patients on GC therapy [25, 26] . Overall, the recent Cochrane review supports the use of bisphosphonates to reduce the risk of vertebral fractures and the prevention and treatment of GCinduced bone loss [27] .
In women of child-bearing age who may wish to conceive after stopping active osteoporosis medication, drugs which have a fast off-set of effect on bone turnover markers, such as denosumab [28] , ibandronate [29] , risedronate [30] or teriparatide [31] , may be considered. (Grade C, Level IV).
Treatment should be continued for as long as the patient is on GC. Expert consensus recommends that therapy may be withdrawn in a subject on GC if BMD is close to normal and the patient is no longer at increased risk of fracture or when GC are stopped [32] (Grade C, Level IV). Once GC therapy is stopped, fracture risks decreased towards baseline values over the following 1 year [6] (Level III).
In conclusion, we hope that this guidance document will provide practical and relevant help to health care practitioners when making clinical decisions on managing their patients with GIO. This article is not meant to be a comprehensive review of all aspects of GIO, neither is it prescriptive. The key messages are to think of bone protection measures in all patients on GC, and, in patients at high risk of osteoporosis, bisphosphonates are the mainstay of treatment. 
Key points
Patients should be prescribed the lowest dose of GC for the shortest period of time that will give good disease control. Patients with a prevalent osteoporotic fracture should receive active osteoporosis medication. Patients who are on GC doses equivalent to prednisolone >5 mg daily should be assessed with BMD measurement and/or FRAX to assess future fracture risk and treatment options. Active osteoporosis therapy should be continued for the duration of GC therapy.
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Appendix 1.
Levels of Evidence and Grades of Recommendation
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